Showing results (461-470 of 635) with videos related to

Sort By:
Pageof 64
International Journal of Cancer|January 25, 2018
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancerPetros Christopoulos, Volker Endris, Farastuk Bozorgmehr, et al.
Cancers|January 24, 2019
Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor SurvivalPetros Christopoulos, Steffen Dietz, Martina Kirchner, et al.
International Journal of Cancer|November 18, 2018
Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panelsVolker Endris, Ivo Buchhalter, Michael Allgäuer, et al.
Clinical Lung Cancer|April 29, 2026
A Retrospective, Multicenter Analysis Within the National Network Genomic Medicine Lung Cancer in Germany to Detect RET Fusions as a Possible Mechanism of Resistance in Patients With EGFR MutationsCornelia Kropf-Sanchen, Nikolaj Frost, Jonas Kuon, et al.
Therapeutic Advances in Medical Oncology|August 19, 2021
Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancerNikolaus Magios, Farastuk Bozorgmehr, Anna-Lena Volckmar, et al.
JTO Clinical and Research Reports|December 9, 2025
The Added Value of Genome-Wide Copy Numbers to Objectively Resolve Clonality of Multiple Tumors With Pulmonary Involvement and Ambiguous or Inconclusive Mutational DiagnosisJurriaan Janssen, Bárbara Andrade Barbosa, Tim R Mocking, et al.
American Journal of Respiratory and Critical Care Medicine|June 27, 2026
Spatial proteomics profiling reveals oncogene-specific immune niches and prognostic markers in NSCLCRajender Nandigama, Bassem Ben Cheikh, Jochen Wilhelm, et al.
Cancers|September 1, 2019
In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma PatientsSimon Heeke, Jonathan Benzaquen, Elodie Long-Mira, et al.
Virchows Archiv : an International Journal of Pathology|June 26, 2012
Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classificationArne Warth, Judith Cortis, Ludger Fink, et al.
International Journal of Cancer|February 28, 2025
Biopsy-derived organoids in personalised early breast cancer care: Challenges of tumour purity and normal cell overgrowth cap their practical utilityPaul Schwerd-Kleine, Roberto Würth, Tasneem Cheytan, et al.
Pageof 64